GlassScriptPhysician profile
Mary V Halbrooks
NPI 1780151514
$3,770.15
in general payments reported to CMS, 2019-2025
32 companies · $856 in 2025
The $856 reported for 2025 was more than what 84% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,024 · 2022: $598 · 2023: $631 · 2024: $662 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $732.32 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.63 | 2021-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $486.82 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $392.23 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Abbvie INC. | $252.51 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.61 | 2021-2024 | Trintellix |
| Amarin Pharma, INC. | $151.64 | 2021 | |
| Glaxosmithkline, LLC. | $122.87 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.13 | 2025 | Caplyta |
| Exact Sciences Corporation | $115.42 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $78.48 | 2021-2025 | Repatha, Otezla |
| Dexcom, INC. | $70.84 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $58.86 | 2022 | |
| Adlon Therapeutics L.P. | $57.73 | 2021 | |
| Astellas Pharma US INC | $56.00 | 2024-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $48.81 | 2022-2023 | |
| Mylan Specialty L.P. | $37.39 | 2021 | |
| Corium, LLC | $31.82 | 2023-2025 | Azstarys |
| Pfizer INC. | $31.22 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $28.17 | 2025 | Rexulti |
| Shield Therapeutics INC | $25.31 | 2025 | |
| Abbott Laboratories | $23.95 | 2023 | Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $23.77 | 2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $19.49 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.83 | 2024 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $15.25 | 2024 | Nuzyra |
| Currax Pharmaceuticals LLC | $14.40 | 2021 | |
| Merck Sharp & Dohme LLC | $14.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.55 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.44 | 2021 | |
| Supernus Pharmaceuticals, INC. | $12.17 | 2021 | |
| Ironshore Pharmaceuticals INC. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Halbrooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.